Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital’s target price indicates a potential upside of 117.05% from the stock’s current price.

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday.

Coya Therapeutics Stock Performance

NASDAQ COYA opened at $6.45 on Thursday. The firm’s fifty day moving average is $6.31 and its two-hundred day moving average is $6.48. Coya Therapeutics has a one year low of $4.75 and a one year high of $10.42. The firm has a market cap of $107.76 million, a PE ratio of -9.92 and a beta of 0.31.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. Research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently made changes to their positions in COYA. Tower Research Capital LLC TRC increased its holdings in shares of Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd acquired a new position in Coya Therapeutics during the fourth quarter worth $59,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter worth $74,000. Northern Trust Corp grew its holdings in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Coya Therapeutics in the fourth quarter valued at $401,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.